Six IPOs raised $1.2 billion this week, tied for the most active week of the year. Yext (YEXT) was the latest in a series of high-growth, high-loss software companies to have well-received IPOs this year. Yext allows businesses to sync...read more
The US IPO market snapped back in the 1Q17, but quarterly biotech activity fell to its lowest level since the 4Q12. Just three of the 25 deals came from biotechs in the 1Q17, compared to seven of the eight in the 1Q16. Recent IPO Tocagen (TOCA)...read more
Tocagen, which is developing a combination gene therapy treatment for brain cancer, raised $85 million by offering 8.5 million shares at $10. It had planned to offer 7.25 million shares at a range of $10 to $12. Tocagen plans to list on the Nasdaq under the...read more
There are six deals on the calendar for the week ahead, after Azul was cleared by regulators to resume its IPO. After not having any deals in the first two month of the year, two tech IPOs this week should make the sector the most active year to date. We...read more
US IPO Weekly Recap: Six IPOs price, Yext pops 22% and Netshoes disappears
Six IPOs raised $1.2 billion this week, tied for the most active week of the year. Yext (YEXT) was the latest in a series of high-growth, high-loss software companies to have well-received IPOs this year. Yext allows businesses to sync...read more
Biotechs stage comeback after slow quarter
The US IPO market snapped back in the 1Q17, but quarterly biotech activity fell to its lowest level since the 4Q12. Just three of the 25 deals came from biotechs in the 1Q17, compared to seven of the eight in the 1Q16. Recent IPO Tocagen (TOCA)...read more
Brain power: Biotech Tocagen prices upsized IPO at $10, the low end of the range
Tocagen, which is developing a combination gene therapy treatment for brain cancer, raised $85 million by offering 8.5 million shares at $10. It had planned to offer 7.25 million shares at a range of $10 to $12. Tocagen plans to list on the Nasdaq under the...read more
US IPO Week Ahead: 5 deals in short week
There are six deals on the calendar for the week ahead, after Azul was cleared by regulators to resume its IPO. After not having any deals in the first two month of the year, two tech IPOs this week should make the sector the most active year to date. We...read more